Heart failure (HF) remains a major cause of mortality, morbidity, and poor quality of life. It is
an area of active research. This article is aimed to give an update on recent advances in all …

Research about heart failure (HF) has made major progress in the last years. We give here
an update on the most recent findings. Landmark trials have established new treatments for …

Cardiac resynchronization therapy (CRT) is one of the most effective therapies for heart
failure with reduced ejection fraction and leads to improved quality of life, reductions in heart …

Abstract Aims The EUropean Comparative Effectiveness Research to Assess the Use of
Primary ProphylacTic Implantable Cardioverter-Defibrillators (EU-CERT-ICD), a prospective …

Cardiac resynchronization therapy (CRT) is one of the most effective therapies for heart
failure with reduced ejection fraction and leads to improved quality of life, reductions in heart …

Aims Patients with non‐ischaemic dilated cardiomyopathy (DCM) are at increased risk of
sudden cardiac death. Identification of patients that may benefit from implantable …

Background The benefit of implantable cardioverter‐defibrillator (ICD) in elderly patients has
been questioned. In the present study, we aimed to analyse the outcome of patients of …

Heart failure (HF) is one of the major challenges in the management of diabetes patients.
Among subjects with diabetes, up to 20% could have HF. Conversely, diabetes prevalence …

Heart failure remains among the most common and morbid health conditions. The Heart
Failure Strategically Focused Research Network (HF SFRN) was funded by the American …

Aims/hypothesis Type 2 diabetes is associated with a high risk of sudden cardiac death
(SCD), but the risk of dying from another cause (non-SCD) is proportionally even higher. The …